Quantcast

New Data Show How Hepatic Encephalopathy Contributes to Burden of Liver Disease

April 11, 2014

LONDON, April 11, 2014 /PRNewswire/ –

        - Hepatic encephalopathy (HE) is associated with a significant increase in
          mortality (58.1% vs. 32.4%), as well as longer hospital stays (8 days vs. 6.8 days)
          and more primary care visits (18.2 vs. 8.7 contacts per patient year) compared to
          similar liver patients without HE[i],[ii]
        - XIFAXAN(R) 550 (rifaximin-alpha) is a cost-effective treatment option for the
          reduction of recurrent hepatic encephalopathy as shown over a number of different time
          horizons and plausible scenarios[iv]

New data presented today at the International Liver Congress show the impact of
hepatic encephalopathy on liver disease patients and healthcare systems.

Liver disease patients who develop HE have almost double the risk of dying compared
with similar liver disease patients without HE over the same time period.[i]

Liver disease patients with HE are admitted to hospital three times more often for
illnesses directly related to their liver disease, compared with liver disease patients
without HE (admission ratio of 3.588:1 for HE patients vs. control group) and are admitted
to hospital one and a half times more often for unrelated illnesses (admission ratio of
1.488:1 for HE patients vs. control group). Liver disease patients with HE will consult
primary care more often following initial diagnosis and stay in hospital longer[ii] than
those without HE, collectively representing a substantial increased use of healthcare
resources.

There is no cure for HE other than liver transplant. However, XIFAXAN(R) 550
(rifaximin-alpha) significantly reduces the risk of further HE episodes.[iii] Treatment
with XIFAXAN(R) 550 versus standard care (lactulose) offers a cost-effective treatment
option for reduction of recurrence of overt HE over a number of different time periods and
plausible scenarios, e.g. incremental cost-effectiveness ratios ranged from GBP13,919 to
GBP21,425 for each year of perfect health gained through treatment with XIFAXAN(R) 550
(QALY) over a five year period.[iv]

Full press release on http://www.norgine.com

i. Morgan C.LI. et al. Mortality associated with hepatic encephalopathy in patients
with severe liver disease. International Liver Congress 2014, Abstract P452

ii. Orr J.G. et al. Resource use associated with hepatic encephalopathy in patients
with liver disease. International liver Congress 2014, Abstract P478

iii. Bass, N.M., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med,
2010; 362(12): 1071-81.

iv. Poole, C., et al. Cost effectiveness of rifaximin-alpha in the reduction of
recurrence of overt hepatic encephalopathy. International liver Congress 2014, Abstract
A-627-0004-00525

        Contacts

        Isabelle Jouin: +44-(0)771-406-1327
        Rachelle Michaels: +44-(0)771-406-1485

SOURCE Norgine B.V.


Source: PR Newswire



comments powered by Disqus